Study partners should be required in preclinical Alzheimer's disease trials.

about

Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review Questions concerning the role of amyloid-β in the definition, aetiology and diagnosis of Alzheimer's disease

P2860

Q57174282-812BDF46-01F3-431A-A89C-F4F1ADD9EB1E Q57800439-8DCE33FA-2BB9-4259-BA0A-A4B826767BC0

P2860

Study partners should be required in preclinical Alzheimer's disease trials.

Item

http://www.wikidata.org/entity/Q46028917

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Study partners should be required in preclinical Alzheimer's disease trials.

@en

Study partners should be required in preclinical Alzheimer's disease trials.

@nl

type

Item

label

Study partners should be required in preclinical Alzheimer's disease trials.

@en

Study partners should be required in preclinical Alzheimer's disease trials.

@nl

prefLabel

Study partners should be required in preclinical Alzheimer's disease trials.

@en

Study partners should be required in preclinical Alzheimer's disease trials.

@nl

P1476

Study partners should be required in preclinical Alzheimer's disease trials.

@en

P275

Creative Commons Attribution 4.0 International

P2860

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Q28078901

Chronic disease long-term drug prevention trials: lessons from the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT).

Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.

Disclosing the disclosure: factors associated with communicating the results of genetic susceptibility testing for Alzheimer's disease.

The A4 study: stopping AD before symptoms begin?

The source of cognitive complaints predicts diagnostic conversion differentially among nondemented older adults.

NIA-funded Alzheimer centers are more efficient than commercial clinical recruitment sites for conducting secondary prevention trials of dementia.

Should we disclose amyloid imaging results to cognitively normal individuals?

The role of disease perceptions and results sharing in psychological adaptation after genetic susceptibility testing: the REVEAL Study

P2888

s13195-017-0327-x

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1186/S13195-017-0327-X

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Joshua D Grill

Jason Karlawish

P5008

ScienceSource

P577

2017-12-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1099704489

http://www.w3.org/2001/XMLSchema#string

P698

29212555

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

biomedical investigative technique

P932

5719524

http://www.w3.org/2001/XMLSchema#string

Study partners should be required in preclinical Alzheimer's disease trials.

about

P2860

P2860

Study partners should be required in preclinical Alzheimer's disease trials.

description

name

type

label

prefLabel

P1433

P1476

P275

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P5008

P577

P6179

P698

P921

P932

P356

P1433

P1476

P275

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P5008

P577

P6179

P698

P921

P932